Utility of Traditional Circulating and Imaging-Based Cardiac Biomarkers in Patients with Predialysis CKD : Clinical Journal of the American Society of Nephrology

Journal Logo


Utility of Traditional Circulating and Imaging-Based Cardiac Biomarkers in Patients with Predialysis CKD

Colbert, Gates*; Jain, Nishank*; de Lemos, James A.; Hedayati, S. Susan*,‡

Author Information
Clinical Journal of the American Society of Nephrology 10(3):p 515-529, March 2015. | DOI: 10.2215/CJN.03600414
  • Free



Cardiovascular disease (CVD) is the leading cause of death in patients with CKD and ESRD, accounting for up to 50% of all deaths (1). Cardiac biomarkers, such as cardiac troponin T (cTnT) and I (cTnI), brain natriuretic peptide (BNP), and N-terminal-pro-BNP (NT-pro-BNP), are commonly used for diagnosing acute myocardial infarction (AMI) and congestive heart failure (CHF) exacerbation. However, chronic elevations of cTnT are observed in 80%–90% of asymptomatic patients with advanced CKD and ESRD (2). cTnT has evolved into an important prognostic factor in dialysis-dependent patients with ESRD, as elevated levels are associated independently with adverse cardiovascular (CV) outcomes (3). Fewer data describe an association between elevated troponins and CVD in patients with non–dialysis-dependent CKD. Other commonly used circulating and imaging-based cardiac biomarkers are also associated with poor CV outcomes in asymptomatic patients with ESRD, but such associations are less clearly established in CKD.

The first aim of this review is to summarize studies that reported associations between traditional cardiac biomarkers, such as cTnT, BNP, NT-pro-BNP, left ventricular mass index (LVMI), coronary artery calcium (CAC) scores, carotid intima-media thickness (cIMT), and clinical outcomes in patients with CKD not yet undergoing maintenance dialysis in an attempt to highlight strengths and limitations of existing data for prognostication. The second aim is to review data that support the utility of these biomarkers for diagnostic purposes in the acute setting. These specific biomarkers were chosen because they are noninvasive tests commonly used in clinical practice. For each biomarker, a general description is given, followed by discussion of levels in CKD, association with outcomes, and, finally, the clinical utility in patients with CKD. Knowledge gaps are identified and areas for future research suggested.

Cardiac Troponin Levels in CKD

Both cTnI and cTnT are biomarkers of cardiac injury that can be measured with standard assays and high-sensitivity (hs) assays, which detect levels about 10-fold lower than the standard assay. However, the upper reference limits for cardiac troponins were originally derived in persons without CKD, and these biomarkers are elevated in up to 80% of patients with asymptomatic CKD and ESRD (2). Troponin elevation in this context does not necessarily indicate acute ischemia from coronary atherosclerosis but may be due to decreased renal clearance or chronic myocardial injury. The mechanisms for this are multifactorial and include myocardial strain from altered hemodynamics, inflammation, endothelial dysfunction, and subendocardial ischemia (3,4) (Figure 1). The effect of renal clearance on circulating troponin concentrations is uncertain (3). Previous literature suggested that cTnT levels, compared with cTnI levels, are more commonly elevated in asymptomatic patients with ESRD (5). Plausible mechanisms for differential elevations include adsorption of cTnI on the dialyzer membrane imparting increased clearance, degradation of the labile cTnI molecule, advanced glycosylation of cTnT imparting decreased clearance, or uremic toxins causing conformational changes in the epitope region and altering the interaction with the assay antibodies (3). Previous clinical data were heavily influenced by differing sensitivities of the cTnT and cTnI assays and are not relevant to contemporary clinical practice. Consensus guidelines, therefore, do not specify a preference for use of cTnI over cTnT in patients with CKD (4). cTnT and cTnI provide largely identical information, and selection between them is typically influenced by laboratory equipment and vendor selection. Unlike the cTnT assay produced by a single manufacturer, cTnI assays are produced by multiple manufacturers using different antibody pairs, and assays are not interchangeable across institutions and studies (6). We therefore chose to focus the following discussion on cTnT.

Figure 1:
Cardiac troponins in patients with CKD. In response to injury, including altered hemodynamics, inflammation, and endothelial dysfunction, cardiac myocytes release troponin T (cTnT) and troponin I (cTnI) into the circulation from the troponin I-troponin T-troponin C (troponin I-T-C) complex present on the thin filament of the contractile apparatus. Serum cTnI and cTnT levels are measured by electrochemiluminescence immunoassay (ECLIA). Compared with cTnI, cTnT assays are standardized. In addition, several reasons explain why serum cTnT, compared with cTnI levels, are elevated in asymptomatic patients with ESRD. In asymptomatic patients with CKD, cardiac troponin levels are associated with various surrogate and hard clinical outcomes.

Higher cutoffs than used in persons without CKD for the diagnosis of AMI were suggested in patients with CKD and ESRD. A cTnT cutoff of 350 ng/L (>10-fold higher than the recommended cutoff for general use) had the best sensitivity (95%) and specificity (97%) for AMI in 284 patients with ESRD presenting with chest pain (7). In 89 patients with asymptomatic CKD stages 3–5, the 95th percentile for hs-cTnT was 139 ng/L, >10-fold higher than that derived in the general population (8), with levels increasing across higher CKD stages. Another study reported that the specificity of a cutoff of >14.0 ng/L, as recommended for diagnosis of AMI in the general population, was much lower in those with an eGFR of ≤60 ml/min per 1.73 m2 (54%) versus >60 ml/min per 1.73 m2 (87%) (9). A higher cutoff of >43.2 ng/L had a much higher specificity (88%) in those with an eGFR≤60 ml/min per 1.73 m2. In addition to higher cutoffs, a rise in troponins compared with previous chronically elevated values, or a rise and/or fall using serial measurements, has been proposed to help distinguish AMI from chronic elevations of cTnT in patients with advanced CKD or ESRD (4,10,11).

Cardiac Troponins and Surrogate Outcomes

cTnT levels were associated with CV events and all-cause mortality in asymptomatic patients with ESRD (12). Although fewer data extend similar associations to patients with nondialysis CKD, several studies reported correlations between cTnT or hs-troponin T (hs-cTnT) with surrogate and hard outcomes (Table 1) (2,1320). Cross-sectional studies revealed an association between higher cTnT and decreased eGFR, as well as measures of left ventricular hypertrophy (LVH). An analysis of the Chronic Renal Insufficiency Cohort (CRIC) reported detectable hs-cTnT (≥3 ng/L) among 81% (Table 1) (2). hs-cTnT was associated with higher LVMI across all LVMI categories, and lower ejection fraction, mainly in the lowest category (≤35%) (2). In another cross-sectional report from CRIC, the highest quartile of hs-cTnT (>24 ng/L) compared with undetectable levels was associated with the presence of LVH and left ventricular systolic dysfunction (LVSD) (21). Among asymptomatic outpatients with CAD and eGFR<60 ml/min per 1.73 m2, elevated hs-cTnT was associated with higher LVMI, lower creatinine- and cystatin-based eGFRs, and higher urine albumin-to-creatinine ratio (UACR) (Table 1) (17). Correlations between cTnT and eGFR were confirmed in British outpatients with atherosclerotic renovascular disease (16). A Japanese study of nondiabetic patients with CKD reported that those with echocardiographic evidence of left ventricular diastolic dysfunction (LVDD) had a significantly higher hs-cTnT level than those without (19).

Table 1:
Studies reporting associations of cardiac troponin T and high-sensitivity cardiac troponin T with outcomes in CKD

Cardiac Troponins and Hard Outcomes

Limited prospective data are available regarding the association of cTnT with CV outcomes in nondialysis patients with CKD. In a British study, cTnT was detectable (≥10 ng/L) in 43% of asymptomatic patients with CKD stages 3–5 (13). Detectable cTnT was associated with increased all-cause mortality at 19 months (Table 1) (13). Similar results for the association of cTnT with increased CV events were reported by Goicoechea et al. in Spanish patients with creatinine clearance <60 ml/min (Table 1) (14). Given low event rates, however, these studies were limited by lack of multivariable analysis and adjustment for confounders (13,14,16). More recently, reports from larger cohorts showed an independent association between hs-cTnT and CV events among patients with CKD in adjusted analyses (Table 1) (15,18).

Clinical Utility of Cardiac Troponins in CKD

In summary, because troponin upper reference limits were originally derived in non-CKD samples, knowledge gaps exist in establishing consensus regarding appropriate diagnostic cutoff values in patients with CKD, as well as the required magnitude of the threshold of change in serial values. The updated consensus definition of AMI requires a rise and/or fall in serial levels, with at least one value above the 99th percentile of the upper reference limit, in addition to appropriate electrocardiographic changes, imaging consistent with myocardial damage, or new regional wall abnormalities (4). However, it does not specify different thresholds for defining AMI in patients with CKD. Nonetheless, it seems reasonable to consider higher threshold values in patients with CKD or rely more heavily on assessment of serial changes to confirm AMI diagnosis. There are no recommendations to support a specific threshold of change in patients with CKD, although recent data in 19 patients with ESRD support the use of a ≥20% change for hs-cTnT (10,11) a value that exceeds analytical variation alone (6). For prognostic purposes, it appears that detectable compared with undetectable troponins portend higher risk for future death and CV events. Future research needs to ascertain whether further work-up or intervention is warranted when clinicians find a detectable troponin in asymptomatic patients with CKD.

BNP and NT-pro-BNP in CKD

NT-pro-BNP and BNP are commonly tested in symptomatic patients suspected of acute CHF exacerbation. In one study, they were elevated in 56% of asymptomatic patients with CKD (22). Pre-pro-BNP is synthesized within the cardiac myocytes in response to ventricular wall stress and stretch (23). After removal of a signaling peptide within the cytosol, pro-BNP is further cleaved into the inactive form (NT-pro-BNP) and the active hormone (BNP) at the time of release from the myocyte or in the circulation (Figure 2). NT-pro-BNP is more stable, with a longer half-life, and may be a better biomarker for chronic volume expansion or stress than is BNP (23). Reduced renal function decreases the fractional plasma clearance of both BNP and NT-pro-BNP, and studies reported correlations between graded elevations in these peptides and declining eGFR or advancing CKD stages (Table 2) (22,2432). The clearance of NT-pro-BNP is predominantly renal, while BNP is also degraded systemically (Figure 2) (23). This may explain the observed correlation of reduced eGFR to a greater extent with NT-pro-BNP than with BNP (23,24), and the increased ratio of NT-pro-BNP/BNP with advancing CKD stages (30), a finding not borne out by all studies. One study reported an equal dependence on renal clearances for both peptides, although most participants had a GFR≥30 ml/min per 1.73 m2 (33), suggesting that clearance may be similar for both until renal function deteriorates to advanced stages.

Figure 2:
Brain natriuretic peptides in patients with CKD. In response to increased stretch or tension, left ventricular myocytes release brain natriuretic peptide (BNP) and N-terminal-pro-BNP (NT-pro-BNP) from precursors. BNP is an active molecule with a short plasma half-life and is degraded in the circulation by enzymatic action. NT-pro-BNP is the inactive form of BNP, with a longer half-life. It is primarily cleared by the kidneys. Reduced eGFR correlates to a greater extent with elevated plasma NT-pro-BNP than to BNP levels. Increased NT-pro-BNP/BNP ratio correlates with advancing CKD stages, especially if the eGFR is <30 ml/min per 1.73 m2. However, both BNP and NT-pro-BNP are associated with surrogate and hard clinical outcomes in asymptomatic patients with CKD.
Table 2:
Studies reporting associations of brain natriuretic protein and N-terminal B-type natriuretic peptide with outcomes in CKD

BNP and Surrogate Outcomes in CKD

Elevated levels of both BNP and NT-pro-BNP are associated with abnormal echocardiographic findings in patients with CKD (Table 2) (20,24,31,32,34). Among those with eGFR<60 ml/min per 1.73 m2, LVMI positively correlated with BNP and NT-pro-BNP levels (24). NT-pro-BNP was independently associated with presence of LVSD in patients with CKD (31) (Table 2). Higher gradations in NT-pro-BNP cutoffs to detect LVSD were reported for increasing CKD stages (31). A Chinese study showed that LVDD positively correlated with Log-NT-pro-BNP (32) (Table 2). In the CRIC study, the highest compared with lowest quartile of NT-pro-BNP was associated with a 3-fold higher odds of LVH and LVSD (20) (Table 2).

BNP and Hard Outcomes in CKD

BNP and NT-pro-BNP are also associated with hard outcomes in CKD (Table 2). In a Japanese study, both BNP and NT-pro-BNP were associated with death and the composite of death and CV events. On the basis of the areas under the curve, the authors concluded that NT-pro-BNP may be a superior marker to BNP for composite events in patients with CKD stages 4 and 5 (versus stages 1–3), although a formal statistical test was not used to determine whether the curves significantly differed (26). Among the African American Study of Kidney Disease and Hypertension cohort, those with elevated NT-pro-BNP had a four times higher hazard for CV events than those with undetectable levels (Table 2) (35). The association was significantly stronger in those with than without proteinuria (interaction P=0.05) (35). In Chinese patients with known CAD, NT-pro-BNP was associated with all-cause death if eGFR was <60 ml/min per 1.73 m2 (36). In addition, the NT-pro-BNP cutoff associated with mortality was higher in patients with CKD (2584 pg/ml) than in persons without CKD (370 pg/ml) (36). Several other studies reported similar associations between NT-pro-BNP, CV events, and all-cause death (Table 2) (3739).

Clinical Utility of NT-pro-BNP and BNP in CKD

To summarize, NT-pro-BNP and BNP can be used for prognostication in patients with CKD because elevated levels are associated with both adverse surrogate and hard outcomes in this population. However, most studies included asymptomatic samples, and clinicians are still left with the important question of how to best interpret elevated BNP and NT-pro-BNP levels for acute CHF diagnosis in symptomatic patients. A study of patients presenting with dyspnea revealed that NT-pro-BNP may be a useful diagnostic test for CHF in patients with and without CKD, although the diagnostic cutoff was higher in those with eGFR<60 ml/min per 1.73 m2 (>1200 pg/ml) than in those with eGFR≥60 ml/min per 1.73 m2 (>450 pg/ml if age <50 years; >900 pg/ml if age ≥50 years) (40). More prospective, well controlled studies are needed to confirm these findings.


CAC as measured by computed tomography is a noninvasive measurement of the burden of coronary atherosclerosis. Patients with CKD have higher CAC scores compared with age-matched controls without CKD, and patients with CKD without baseline calcification exhibit higher incidence rates of developing future de novo CAC (41,42). Cross-sectional analyses have reported a graded relationship between lower eGFR and increasing CAC (41). These associations were attenuated after adjustment for traditional CV risk factors, such as diabetes, but remained statistically significant for patients with an eGFR<30 ml/min per 1.73 m2 (42). It is not entirely clear whether a decline in eGFR plays a mechanistic role for developing de novo CAC and CAC progression. Interestingly, several analyses reported higher baseline CAC and CAC progression to be associated with eGFR decline and worsening proteinuria (4345) (Table 3). A plausible explanation may be that the progression of CAC and CKD are collinear because of the presence of similar risk factors for both disease processes.

Table 3:
Studies reporting association of coronary artery calcium with outcomes in CKD

Both traditional and nontraditional CV risk factors are associated with the presence and severity of CAC in patients with CKD who are not undergoing dialysis. Traditional factors explored included advanced age, white race, male sex, higher body mass index, and diabetes mellitus, in particular (4648). A retrospective study of patients with stages 2–5 CKD with well controlled BP reported higher prevalence of CAC in patients with diabetes than in nondiabetic patients (77% versus 33%) (Table 3) (46), and another study found faster progression in CAC among diabetic patients with CKD than in those without diabetes (48). We previously reported in a multiethnic, population-based asymptomatic cohort that three nontraditional risk factors—calcium-phosphorus product, homocysteine, and osteoprotegerin—were independently associated with high CAC scores, and diminished the magnitude of the association between the presence of CKD and elevated CAC, suggesting that they may play mechanistic roles in the development of CAC (49). Others reported similar associations between elevated serum phosphorus and CAC in patients with CKD (48).

CAC and Clinical Outcomes

Fewer data are available on unfavorable clinical implications of CAC in predialysis CKD versus ESRD samples. The few observational studies reporting associations of CAC with adverse outcomes are limited by low event rates, limited follow-up, or ethnic homogeneity (Table 3) (46,47,50,51). A study of a predominantly Latino diabetic cohort reported that those in the highest compared with the lowest quartile of baseline CAC had a higher hazard of all-cause mortality at 39 months (47). During a 25-month follow-up, there was four times higher risk of CV death or AMI among outpatients with stages 2–5 CKD and baseline CAC scores >100 Agatston units (AU) compared with ≤100 AU (50). Finally, in renal transplant recipients, CAC score assessed at the inception of the cohort was associated with the composite of CV death, AMI, stroke, transient ischemic attack, and revascularization at 2.3 years (Table 3) (51). However, models were overadjusted for the few events in the last two studies (50,51).

Clinical Utility of CAC in CKD

CAC is being used as a screening test to assess risk of future CV events in patients without CKD who are at intermediate CV risk because it may add to the prognostic utility of the Framingham Risk Score (52,53). Asymptomatic persons without CKD and without CAC have a very low risk of CV events, whereas those with scores >400 AU have elevated risk similar to that in patients with diabetes or peripheral vascular disease (54). Studies in patients without CKD reported a strong correlation between CAC and total atherosclerotic plaque burden at the individual level (r=0.90) (55). Although current guidelines do not recommend the routine use of CAC for risk stratification, they do recommend its use to inform treatment decision-making in patients without CKD if a risk-based treatment decision is uncertain after quantitative risk assessment using traditional CV risk factors (56). However, it is too early to recommend the standard use of CAC for risk stratification in patients with CKD because it remains unclear whether such calcific lesions in a coronary artery segment increase or decrease biomechanical stability of atherosclerotic plaques in CKD (57). Similarly, it is not known whether increased CAC or its progression truly plays a mechanistic role in the development of future CV events or is merely a surrogate for other CV risk factors in patients with CKD. Finally, there are not enough data to show that CAC is a modifiable risk factor in CKD. For example, it is not known whether the reduction of calcium or phosphate using various binders persistently influences regression of CAC in CKD or whether CAC regression translates to improved outcomes (58).

LV Mass or LV Dysfunction in CKD

LVH and abnormal LV function, based on echocardiographic parameters, are highly prevalent among patients with CKD who initiate dialysis. According to a Canadian cohort, 74% have LVH, 36% have LV dilation, and 15% have LVSD (59). Higher baseline LVMI is associated with severity of CKD as well as progression, but it is not clear whether this is independent of high BP.

In a cross-sectional study of diabetic patients, severity of CKD stage paralleled increases in LVMI and decreases in LV ejection fraction (LVEF) (Table 4) (60). Patients with CKD stages 3–5 and LVH had lower eGFR and greater proteinuria than patients without LVH, as well as a weak inverse correlation between LVMI and eGFR (61). However, in multivariable models that included systolic BP and body mass index, eGFR was not independently associated with LVH (61). Another cross-sectional study did report a correlation between urinary protein-to-creatinine ratio and LVMI, independent of systolic BP, although a similar correlation was not observed with eGFR (62). These studies were limited by lack of controls without CKD. Interestingly, there were higher LV mass and greater degree of LVDD, but no difference in LVEF, among patients with CKD compared with age- and sex-matched controls according to univariate analyses (63). However, pulse pressure was significantly higher in patients with CKD than in controls, which could account for the observed differences (63). Finally, three prospective longitudinal studies reported changes in LV geometry to independently correlate with eGFR decline and progression to ESRD (Table 4) (6466).

Table 4:
Studies reporting associations of left ventricular mass and function with outcomes in CKD

LV Mass, LV Dysfunction, and Clinical Outcomes

LVMI was independently associated with increased all-cause and CV mortality in patients initiating dialysis in a prospective study, even after adjustment for age, CAD, diabetes mellitus, and systolic BP (59). These findings were extended to outpatients with CKD stages 3–5, in whom higher LVMI and LVEF <55% versus ≥55% at baseline were associated with CV events, including death, AMI, sustained ventricular arrhythmia, hospitalization for unstable angina, congestive heart failure, transient ischemic attack, or stroke at 26 months (Table 4) (67).

Clinical Utility of LV Mass or LV Dysfunction in CKD

Although these data suggest that LVH is associated with CKD progression and CV events, elevated SBP and pulse pressure, which are highly prevalent in this patient population, may be major confounders in these analyses. In addition, lack of well controlled prospective studies limit the utility of echocardiographic parameters in predicting outcomes in clinical practice. Future studies need to analyze how changes in LV mass and function may be used to prognosticate hard clinical outcomes.


The cIMT has become a frequently studied sonographic marker of early atherosclerotic changes in vessels. The thickening of the intima-media complex not only reflects a local vessel change in the carotid but could indicate a systemic change in all vessel walls. It may also predict future risk for CV events. The ease and safety of this imaging study allow its use as a potential new biomarker for systemic atherosclerosis in high-risk patient populations, such as predialysis patients with CKD. Several studies, mostly cross-sectional, suggested that cIMT measurements were elevated in CKD individuals, as reviewed later in this article (Table 5).

Table 5:
Studies reporting associations of carotid intima-media thickness with outcomes in CKD

In a case-control study, case-patients with a serum creatinine ≥0.40 mmol/L had significantly higher cIMT than controls (Table 5) (68). Among patients with CKD stages 3–5, cIMT measurements were significantly higher if eGFR was <60 ml/min per 1.73 m2 than >60 ml/min per 1.73 m2 (69). Another study reported a weak but statistically significant correlation between lower eGFR and higher mean maximum wall thickness measured along 12 carotid segments, after adjustment for age and sex (70). Two studies revealed small but statistically significant stepwise increases in cIMT measurements with higher CKD stages (Table 5) (71,72).

cIMT and Clinical Outcomes

There are conflicting data on whether cIMT is associated with death or CV events in predialysis patients with CKD. A Chinese study of 203 patients with stages 3 or 4 CKD reported a statistically significant trend for higher adverse CV events for increasing cIMT quartiles (Table 5) (73). In a longitudinal study of 3364 outpatients with and without CKD, lower creatinine clearance and higher cIMT were associated with fatal and nonfatal vascular events (74). However, in a study of nondiabetic outpatients with eGFR<60 ml/min per 1.73 m2, carotid plaque burden but not cIMT was associated with fatal or nonfatal acute coronary syndrome (ACS) or stroke (75). Similarly, Marcos et al. did not show a significant association between the severity of cIMT and CV events or death (76). cIMT could not be used to reliably discriminate prevalent CVD in a group of outpatients with CKD (77). Finally, a recent analysis of the Multi-Ethnic Study of Atherosclerosis cohort revealed that CAC was superior to cIMT for CVD prediction in patients with and those without CKD (Table 5) (78).

Clinical Utility of cIMT in CKD

Although studies suggested that cIMT measurements are higher in patients with CKD than in those without CKD, the differences were small and of unclear clinical relevance. In addition, observed increases in cIMT with decreasing eGFR or advancing CKD stages could be confounded by other traditional risk factors that cause CKD progression, such as uncontrolled hypertension or diabetes. At present, cIMT has not proven to be a reliable predictor of hard outcomes in predialysis patients with CKD. Currently, the standardization of cIMT measurement is a major challenge, and it is not routinely recommended in clinical practice for risk assessment in the general population, let alone patients with CKD (56). Further research needs to delineate whether cIMT can be reliably measured in patients with CKD and used as a screening test for CV risk stratification in this patient population.


In summary, Figure 3 outlines the potential uses of an ideal circulating and imaging cardiac biomarker, which should be similar in patients with predialysis CKD. However, given current knowledge gaps, more data need to become available before all of these markers can be reliably used in this patient population. Observational studies reporting associations between cTnT and NT-pro-BNP and decline in eGFR in nondialysis patients with CKD may be confounded by decreased renal clearance of these biomarkers in the setting of advanced CKD. The same traditional and nontraditional factors associated with CAC are likely also correlated with CKD progression. Although the evidence presented suggests that these biomarkers may be used to predict future CV events in asymptomatic patients with CKD, future studies need to confirm reliable cutoffs for the utility of these biomarkers as diagnostic tests in patients presenting with symptoms concerning for ACS or acute CHF. In addition, it remains unclear whether cardiac biomarkers such as cTnT, NT-pro-BNP, BNP, CAC, and cIMT in asymptomatic patients with CKD are modifiable and amenable to interventions to reduce future CV risk. Further studies are needed to inform whether better risk stratification scores that include novel in addition to traditional biomarkers should be developed to quantify CV risk in patients with CKD.

Figure 3:
Utility of cardiac biomarkers in patients with CKD. Ideally, cardiac biomarkers should be useful in diagnosing atherosclerotic cardiovascular disease (ASCVD), risk-stratifying patients according to disease severity, monitoring ASCVD progression, identifying patients who may benefit from early intervention, and/or monitoring response to such interventions. The potential utility of circulating and imaging cardiac biomarkers in patients with CKD is similar. It includes one or many of the features of an ideal biomarker in relation with ASCVD.


J.A.de L. has received grant support and consulting income from Roche Diagnostics and Abbott Diagnostics.


This work is supported in part by the University of Texas Southwestern Medical Center O’Brien Kidney Research Core Center (P30-DK079328). N.J. is supported by a grant from the American Heart Association Clinical Research Program (12CRP11830004). S.S.H. receives support from a Veterans Affairs MERIT grant (CX000217) and a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK085512).

The content is solely the responsibility of the authors and does not necessarily represent the official views of the American Heart Association, the National Institutes of Health, or the Department of Veterans Affairs.

Published online ahead of print. Publication date available at www.cjasn.org.


1. U.S. Renal Data System: USRDS 2010 Annual Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010
2. Dubin RF, Li Y, He J, Jaar BG, Kallem R, Lash JP, Makos G, Rosas SE, Soliman EZ, Townsend RR, Yang W, Go AS, Keane M, Defilippi C, Mishra R, Wolf M, Shlipak MGCRIC Study Investigators: Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: A cross-sectional study in the chronic renal insufficiency cohort (CRIC). BMC Nephrol 14: 229, 2013
3. Jain N, Hedayati SS: How should clinicians interpret cardiac troponin values in patients with ESRD? Semin Dial 24: 398–400, 2011
4. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BR, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow JJ, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Morais J, Aguiar C, Almahmeed W, Arnar DO, Barili F, Bloch KD, Bolger AF, Botker HE, Bozkurt B, Bugiardini R, Cannon C, de Lemos J, Eberli FR, Escobar E, Hlatky M, James S, Kern KB, Moliterno DJ, Mueller C, Neskovic AN, Pieske BM, Schulman SP, Storey RF, Taubert KA, Vranckx P, Wagner DRJoint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial InfarctionAuthors/Task Force Members ChairpersonsBiomarker SubcommitteeECG SubcommitteeImaging SubcommitteeClassification SubcommitteeIntervention SubcommitteeTrials & Registries SubcommitteeTrials & Registries SubcommitteeTrials & Registries SubcommitteeTrials & Registries SubcommitteeESC Committee for Practice Guidelines (CPG)Document Reviewers: Third universal definition of myocardial infarction. J Am Coll Cardiol 60: 1581–1598, 2012
5. Apple FS, Murakami MM, Pearce LA, Herzog CA: Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 106: 2941–2945, 2002
6. de Lemos JA: Increasingly sensitive assays for cardiac troponins: A review. JAMA 309: 2262–2269, 2013
7. Ryu DR, Park JT, Chung JH, Song EM, Roh SH, Lee JM, An HR, Yu M, Pyun WB, Shin GJ, Kim SJ, Kang DH, Choi KB: A more appropriate cardiac troponin T level that can predict outcomes in end-stage renal disease patients with acute coronary syndrome. Yonsei Med J 52: 595–602, 2011
8. Chotivanawan T, Krittayaphong R: Normal range of serum highly-sensitive troponin-T in patients with chronic kidney disease stage 3-5. J Med Assoc Thai 95[Suppl 2]: S127–S132, 2012
9. Chenevier-Gobeaux C, Meune C, Freund Y, Wahbi K, Claessens YE, Doumenc B, Zuily S, Riou B, Ray P: Influence of age and renal function on high-sensitivity cardiac troponin T diagnostic accuracy for the diagnosis of acute myocardial infarction. Am J Cardiol 111: 1701–1707, 2013
10. Khalili H, de Lemos JA: What constitutes a relevant change in high-sensitivity troponin values over serial measurement? Clin Chem 60: 803–805, 2014
11. Aakre KM, Røraas T, Petersen PH, Svarstad E, Sellevoll H, Skadberg Ø, Sæle K, Sandberg S: Weekly and 90-minute biological variations in cardiac troponin T and cardiac troponin I in hemodialysis patients and healthy controls. Clin Chem 60: 838–847, 2014
12. Dierkes J, Domröse U, Westphal S, Ambrosch A, Bosselmann HP, Neumann KH, Luley C: Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation 102: 1964–1969, 2000
13. Abbas NA, John RI, Webb MC, Kempson ME, Potter AN, Price CP, Vickery S, Lamb EJ: Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. Clin Chem 51: 2059–2066, 2005
14. Goicoechea M, Garca de Vinuesa S, Gómez-Campderá F, Gutierrez MJ, Blanco P, Amann R, Luño J: Clinical significance of cardiac troponin T levels in chronic kidney disease patients: Predictive value for cardiovascular risk. Am J Kidney Dis 43: 846–853, 2004
15. Scheven L, de Jong PE, Hillege HL, Lambers Heerspink HJ, van Pelt LJ, Kootstra JE, Bakker SJ, Gansevoort RTPREVEND study group: High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. Eur Heart J 33: 2272–2281, 2012
16. Chrysochou C, Manzoor S, Wright J, Roberts SA, Wood G, McDowell G, Kalra PA: Role of renal function and cardiac biomarkers (NT-proBNP and Troponin) in determining mortality and cardiac outcome in atheromatous renovascular disease. Kidney Blood Press Res 32: 373–379, 2009
17. deFilippi C, Seliger SL, Kelley W, Duh SH, Hise M, Christenson RH, Wolf M, Gaggin H, Januzzi J: Interpreting cardiac troponin results from high-sensitivity assays in chronic kidney disease without acute coronary syndrome. Clin Chem 58: 1342–1351, 2012
18. Hasegawa M, Ishii J, Kitagawa F, Kanayama K, Takahashi H, Ozaki Y, Yuzawa Y: Prognostic value of highly sensitive troponin T on cardiac events in patients with chronic kidney disease not on dialysis. Heart Vessels 28: 473–479, 2013
19. Kitagawa M, Sugiyama H, Morinaga H, Inoue T, Takiue K, Kikumoto Y, Uchida HA, Kitamura S, Maeshima Y, Toh N, Nakamura K, Ito H, Makino H: Serum high-sensitivity cardiac troponin T is a significant biomarker of left-ventricular diastolic dysfunction in subjects with non-diabetic chronic kidney disease. Nephron Extra 1: 166–177, 2011
20. Mishra RK, Li Y, Ricardo AC, Yang W, Keane M, Cuevas M, Christenson R, deFilippi C, Chen J, He J, Kallem RR, Raj DS, Schelling JR, Wright J, Go AS, Shlipak MGChronic Renal Insufficiency Cohort Investigators: Association of N-terminal pro-B-type natriuretic peptide with left ventricular structure and function in chronic kidney disease (from the Chronic Renal Insufficiency Cohort [CRIC]). Am J Cardiol 111: 432–438, 2013
21. Mishra RK, Li Y, DeFilippi C, Fischer MJ, Yang W, Keane M, Chen J, He J, Kallem R, Horwitz EJ, Rafey M, Raj DS, Go AS, Shlipak MGCRIC Study Investigators: Association of cardiac troponin T with left ventricular structure and function in CKD. Am J Kidney Dis 61: 701–709, 2013
22. DeFilippi CR, Fink JC, Nass CM, Chen H, Christenson R: N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis 46: 35–44, 2005
23. Panteghini M, Clerico A: Understanding the clinical biochemistry of N-terminal pro-B-type natriuretic peptide: The prerequisite for its optimal clinical use. Clin Lab 50: 325–331, 2004
24. Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, Lamb EJ: B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: Relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 46: 610–620, 2005
25. Yi S, Contreras G, Miller ER, Appel LJ, Astor BC: Correlates of N-terminal prohormone brain natriuretic peptides in African Americans with hypertensive chronic kidney disease: the African American Study of Kidney Disease and Hypertension. Am J Nephrol 29: 292–298, 2009
26. Horii M, Matsumoto T, Uemura S, Sugawara Y, Takitsume A, Ueda T, Nakagawa H, Nishida T, Soeda T, Okayama S, Somekawa S, Ishigami K, Takeda Y, Kawata H, Kawakami R, Saito Y: Prognostic value of B-type natriuretic peptide and its amino-terminal proBNP fragment for cardiovascular events with stratification by renal function. J Cardiol 61: 410–416, 2013
27. Bruch C, Reinecke H, Stypmann J, Rothenburger M, Schmid C, Breithardt G, Wichter T, Gradaus R: N-terminal pro-brain natriuretic peptide, kidney disease and outcome in patients with chronic heart failure. J Heart Lung Transplant 25: 1135–1141, 2006
28. Bodlaj G, Hubmann R, Saleh K, Biesenbach G, Pohanka E, Stojakovic T, Berg J: Serum levels of N-terminal pro-B-type natriuretic peptide are associated with allograft function in recipients of renal transplants. Wien Klin Wochenschr 121: 631–637, 2009
29. Yasuda K, Kimura T, Sasaki K, Obi Y, Iio K, Yamato M, Rakugi H, Isaka Y, Hayashi T: Plasma B-type natriuretic peptide level predicts kidney prognosis in patients with predialysis chronic kidney disease. Nephrol Dial Transplant 27: 3885–3891, 2012
30. Spanaus KS, Kronenberg F, Ritz E, Schlapbach R, Fliser D, Hersberger M, Kollerits B, König P, von Eckardstein AMild-to-Moderate Kidney Disease Study Group: B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study. Clin Chem 53: 1264–1272, 2007
31. Lee JE, Choi SY, Huh W, Park SW, Kim DJ, Oh HY, Kim YG: N-terminal pro-brain natriuretic peptide levels predict left ventricular systolic function in patients with chronic kidney disease. J Korean Med Sci 24[Suppl]: S63–S68, 2009
32. Yang Y, Wang Y, Shi ZW, Zhu DL, Gao PJ: Association of E/E’ and NT-proBNP with renal function in patients with essential hypertension. PLoS ONE 8: e54513, 2013
33. van Kimmenade RR, Januzzi JL Jr, Bakker JA, Houben AJ, Rennenberg R, Kroon AA, Crijns HJ, van Dieijen-Visser MP, de Leeuw PW, Pinto YM: Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol 53: 884–890, 2009
34. Khan IA, Fink J, Nass C, Chen H, Christenson R, deFilippi CR: N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol 97: 1530–1534, 2006
35. Astor BC, Yi S, Hiremath L, Corbin T, Pogue V, Wilkening B, Peterson G, Lewis J, Lash JP, Van Lente F, Gassman J, Wang X, Bakris G, Appel LJ, Contreras G: N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: The African American Study of Kidney Disease and Hypertension (AASK). Circulation 117: 1685–1692, 2008
36. Fu S, Luo L, Ye P, Yi S, Liu Y, Zhu B, Wang L, Xiao T, Bai Y: The ability of NT-proBNP to detect chronic heart failure and predict all-cause mortality is higher in elderly Chinese coronary artery disease patients with chronic kidney disease. Clin Interv Aging 8: 409–417, 2013
37. Bruch C, Fischer C, Sindermann J, Stypmann J, Breithardt G, Gradaus R: Comparison of the prognostic usefulness of N-terminal pro-brain natriuretic Peptide in patients with heart failure with versus without chronic kidney disease. Am J Cardiol 102: 469–474, 2008
38. Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH: Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 49: 2256–2262, 2006
39. Oterdoom LH, de Vries AP, van Ree RM, Gansevoort RT, van Son WJ, van der Heide JJ, Navis G, de Jong PE, Gans RO, Bakker SJ: N-terminal pro-B-type natriuretic peptide and mortality in renal transplant recipients versus the general population. Transplantation 87: 1562–1570, 2009
40. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, Chae C, Januzzi JL Jr: Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 47: 91–97, 2006
41. Budoff MJ, Rader DJ, Reilly MP, Mohler ER 3rd, Lash J, Yang W, Rosen L, Glenn M, Teal V, Feldman HICRIC Study Investigators: Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis 58: 519–526, 2011
42. Lamprea-Montealegre JA, McClelland RL, Astor BC, Matsushita K, Shlipak M, de Boer IH, Szklo M: Chronic kidney disease, plasma lipoproteins, and coronary artery calcium incidence: The Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 33: 652–658, 2013
43. Chang JH, Sung JY, Nam HE, Jeong H, Jo MY, Hwang YH, Jung JY, Lee HH, Chung W, Sung YM, Kim S: Role of coronary artery calcification score on the decrease in GFR among subjects with CT coronary angiography. Clin Exp Hypertens 34: 24–30, 2012
44. Garland JS, Holden RM, Hopman WM, Gill SS, Nolan RL, Morton AR: Body mass index, coronary artery calcification, and kidney function decline in stage 3 to 5 chronic kidney disease patients. J Ren Nutr 23: 4–11, 2013
45. Maahs DM, Jalal D, Chonchol M, Johnson RJ, Rewers M, Snell-Bergeon JK: Impaired renal function further increases odds of 6-year coronary artery calcification progression in adults with type 1 diabetes: The CACTI study. Diabetes Care 36: 2607–2614, 2013
46. Russo D, Morrone LF, Imbriaco M, Pota A, Russo L, Scognamiglio B, Sorrentino R: Coronary artery calcification and outcomes in diabetic patients with and without chronic kidney disease. Blood Purif 36: 17–20, 2013
47. Chiu YW, Adler SG, Budoff MJ, Takasu J, Ashai J, Mehrotra R: Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney Int 77: 1107–1114, 2010
48. Stavroulopoulos A, Porter CJ, Pointon K, Monaghan JM, Roe SD, Cassidy MJ: Evolution of coronary artery calcification in patients with chronic kidney disease Stages 3 and 4, with and without diabetes. Nephrol Dial Transplant 26: 2582–2589, 2011
49. Baber U, de Lemos JA, Khera A, McGuire DK, Omland T, Toto RD, Hedayati SS: Non-traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort. Kidney Int 73: 615–621, 2008
50. Russo D, Corrao S, Battaglia Y, Andreucci M, Caiazza A, Carlomagno A, Lamberti M, Pezone N, Pota A, Russo L, Sacco M, Scognamiglio B: Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis. Kidney Int 80: 112–118, 2011
51. Nguyen PT, Henrard S, Coche E, Goffin E, Devuyst O, Jadoul M: Coronary artery calcification: A strong predictor of cardiovascular events in renal transplant recipients. Nephrol Dial Transplant 25: 3773–3778, 2010
52. D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson PCHD Risk Prediction Group: Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation. JAMA 286: 180–187, 2001
53. Budoff MJ, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG, Greenland P, Guerci AD, Lima JA, Rader DJ, Rubin GD, Shaw LJ, Wiegers SEAmerican Heart Association Committee on Cardiovascular Imaging and InterventionAmerican Heart Association Council on Cardiovascular Radiology and InterventionAmerican Heart Association Committee on Cardiac Imaging, Council on Clinical Cardiology: Assessment of coronary artery disease by cardiac computed tomography: A scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 114: 1761–1791, 2006
54. Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM, Lauer MS, Post WS, Raggi P, Redberg RF, Rodgers GP, Shaw LJ, Taylor AJ, Weintraub WS, Harrington RA, Abrams J, Anderson JL, Bates ER, Grines CL, Hlatky MA, Lichtenberg RC, Lindner JR, Pohost GM, Schofield RS, Shubrooks SJ Jr, Stein JH, Tracy CM, Vogel RA, Wesley DJAmerican College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography)Society of Atherosclerosis Imaging and PreventionSociety of Cardiovascular Computed Tomography: ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: A report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation 115: 402–426, 2007
55. Rumberger JA, Sheedy PF 3rd, Breen JF, Schwartz RS: Coronary calcium, as determined by electron beam computed tomography, and coronary disease on arteriogram. Effect of patient’s sex on diagnosis. Circulation 91: 1363–1367, 1995
56. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB Sr, Gibbons R, Greenland P, Lackland DT, Levy D, O’Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PWAmerican College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63[25 Pt B]: 2935–2959, 2014
57. Beckman JA, Ganz J, Creager MA, Ganz P, Kinlay S: Relationship of clinical presentation and calcification of culprit coronary artery stenoses. Arterioscler Thromb Vasc Biol 21: 1618–1622, 2001
58. McCullough PA, Chinnaiyan KM: Annual progression of coronary calcification in trials of preventive therapies: A systematic review. Arch Intern Med 169: 2064–2070, 2009
59. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36: 286–290, 1989
60. Chen SC, Chang JM, Liu WC, Tsai YC, Tsai JC, Su HM, Hwang SJ, Chen HC: Stepwise increases in left ventricular mass index and decreases in left ventricular ejection fraction correspond with the stages of chronic kidney disease in diabetes patients. Exp Diabetes Res 2012: 789325, 2012
61. Nitta K, Iimuro S, Imai E, Matsuo S, Makino H, Akizawa T, Watanabe T, Ohashi Y, Hishida A: Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease. Clin Exp Nephrol 17: 730–742, 2013
62. McQuarrie EP, Patel RK, Mark PB, Delles C, Connell J, Dargie HJ, Steedman T, Jardine AG: Association between proteinuria and left ventricular mass index: A cardiac MRI study in patients with chronic kidney disease. Nephrol Dial Transplant 26: 933–938, 2011
63. Edwards NC, Ferro CJ, Townend JN, Steeds RP: Aortic distensibility and arterial-ventricular coupling in early chronic kidney disease: A pattern resembling heart failure with preserved ejection fraction. Heart 94: 1038–1043, 2008
64. Chen SC, Su HM, Hung CC, Chang JM, Liu WC, Tsai JC, Lin MY, Hwang SJ, Chen HC: Echocardiographic parameters are independently associated with rate of renal function decline and progression to dialysis in patients with chronic kidney disease. Clin J Am Soc Nephrol 6: 2750–2758, 2011
65. Chen SC, Chang JM, Yeh SM, Su HM, Chen HC: Association of uric acid and left ventricular mass index with renal outcomes in chronic kidney disease. Am J Hypertens 26: 243–249, 2013
66. Park M, Shlipak MG, Katz R, Agarwal S, Ix JH, Hsu CY, Peralta CA: Subclinical cardiac abnormalities and kidney function decline: The multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol 7: 1137–1144, 2012
67. Chen SC, Chang JM, Liu WC, Huang JC, Tsai JC, Lin MY, Su HM, Hwang SJ, Chen HC: Echocardiographic parameters are independently associated with increased cardiovascular events in patients with chronic kidney disease. Nephrol Dial Transplant 27: 1064–1070, 2012
68. Zoungas S, Cameron JD, Kerr PG, Wolfe R, Muske C, McNeil JJ, McGrath BP: Association of carotid intima-medial thickness and indices of arterial stiffness with cardiovascular disease outcomes in CKD. Am J Kidney Dis 50: 622–630, 2007
69. Lemos MM, Jancikic AD, Sanches FM, Christofalo DM, Ajzen SA, Carvalho AB, Draibe SA, Canziani ME: Intima-media thickness is associated with inflammation and traditional cardiovascular risk factors in non-dialysis-dependent patients with chronic kidney disease. Nephron Clin Pract 115: c189–c194, 2010
70. Tanaka M, Abe Y, Furukado S, Miwa K, Sakaguchi M, Sakoda S, Kitagawa K: Chronic kidney disease and carotid atherosclerosis. J Stroke Cerebrovasc Dis 21: 47–51, 2012
71. Aggarwal HK, Jain D, Lathar M, Yadav RK, Sawhney A: Lipoprotein-A and carotid intima media thickness as cardiovascular risk factors in patients of chronic kidney disease. Ren Fail 32: 647–652, 2010
72. Zhou W, Ni Z, Yu Z, Shi B, Wang Q: Brain natriuretic peptide is related to carotid plaques and predicts atherosclerosis in pre-dialysis patients with chronic kidney disease. Eur J Intern Med 23: 539–544, 2012
73. Szeto CC, Chow KM, Woo KS, Chook P, Ching-Ha Kwan B, Leung CB, Kam-Tao Li P: Carotid intima media thickness predicts cardiovascular diseases in Chinese predialysis patients with chronic kidney disease. J Am Soc Nephrol 18: 1966–1972, 2007
74. Desbien AM, Chonchol M, Gnahn H, Sander D: Kidney function and progression of carotid intima-media thickness in a community study. Am J Kidney Dis 51: 584–593, 2008
75. Kim JK, Song YR, Kim MG, Kim HJ, Kim SG: Clinical significance of subclinical carotid atherosclerosis and its relationship with echocardiographic parameters in non-diabetic chronic kidney disease patients. BMC Cardiovasc Disord 13: 96, 2013
76. Marcos AG, Watanabe R, Lemos MM, Canziani ME: [Evaluation of intima-media thickness in patients with chronic kidney disease not on dialysis: a prospective study of 24 month]. J Bras Neurol 36: 35–41, 2014
77. Adeseun GA, Xie D, Wang X, Joffe MM, Mohler ER 3rd, Townsend RR, Budoff M, Rosas SE: Carotid plaque, carotid intima-media thickness, and coronary calcification equally discriminate prevalent cardiovascular disease in kidney disease. Am J Nephrol 36: 342–347, 2012
78. Matsushita K, Sang Y, Ballew SH, Shlipak M, Katz R, Rosas SE, Peralta CA, Woodward M, Kramer HJ, Jacobs DR, Sarnak MJ, Coresh J: Subclinical atherosclerosis measures for cardiovascular prediction in CKD [published online ahead of print August 21, 2014]. J Am Soc Nephrol doi: 10.1681/ASN.2014020173

chronic kidney disease; cardiovascular disease; coronary calcification; clinical epidemiology

Copyright © 2015 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.